CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in the number of recognized clinical laboratories
4.1.2. Increase in the number of IVD test volumes
4.1.3. Increase in adoption of multianalyte controls
4.1.4. High demand for external quality assessment support
4.1.5. Rising adoption of third party quality control products
4.2. Market Restraints & Challenges
4.2.1. Low reimbursement scenario for IVD tests
4.2.2. High additional costs involved in quality control and budget constraints
4.2.3. Stringent product approval process
4.3. Market Opportunities
4.3.1. Emerging markets
4.3.2. Rising demand for multi-analyte controls
CHAPTER 5 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET – BY PRODUCT & SERVICE
5.1. Quality Control Products
5.1.1. Serum/Plasma-Based Controls
5.1.2. Whole Blood-Based Controls
5.1.3. Urine-Based Controls
5.1.4. Other Source-Based IVD Quality Controls
5.2. Data Management Solutions
5.3. Quality Assurance Services
CHAPTER 6 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET – BY MANUFACTURER TYPE
6.1. Third-Party Control Manufacturers
6.2.1. Independent Controls
6.2.2. Instrument-Specific Controls
6.2. Original Equipment Manufacturers (OEMS)
CHAPTER 7 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET – BY APPLICATION
7.1. Immunochemistry/Immunoassay
7.2. Clinical Chemistry
7.3. Hematology
7.4. Molecular Diagnostics
7.5. Coagulation & Hemostasis
7.6. Microbiology
7.7. Others
CHAPTER 8 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET – BY END USER
8.1. Hospitals
8.2. Clinical Laboratories
8.3. Academic & Research Institutes
8.4. Others
CHAPTER 9 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET - COMPANY PROFILES
10.1. Abbott Laboratories Inc.
10.2. Roche Diagnostics
10.3. Bio-Rad Laboratories
10.4. Thermo Fisher Scientific, Inc.
10.5. Helena Laboratories
10.6. Seracare Life Sciences, Inc.
10.7. Quidel Corporation, Inc.
10.8. Randox Laboratories Ltd.
10.9. Siemens AG
10.10. Technopath Clinical Diagnostics
10.11. Ortho Clinical Diagnostics, Inc.
10.12. Sun Diagnostics, LLC
10.13. Sysmex Corporation
10.14. Danaher Corporation
10.15. Hologic, Inc.
CHAPTER 11 GLOBAL IN VITRO DIAGNOSTICS QUALITY CONTROL MARKET - COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
